Section of Hematology / Oncology
Instructor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|MD||2008||Stanford Univ. School of Medicine||Medicine
|Residency||2011||University of Chicago||Internal Medicine
|Chief Resident||2012||MacNeal Hospital||Internal Medicine
|Fellowship||2015||University of Chicago||Hematology/Oncology
|Fellowship||2016||University of Chicago||Clinical Pharmacology * Pharmacogenomics
Dr. Curran’s research is focused on investigating mechanisms of immune resistance in leukemia. She utilizes murine models to identify therapeutic strategies to enhance anti-leukemia immunity, with the goal of translating these findings to clinical trials in humans.
Acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, stem cell transplantation, adolescent and young adult oncology (with a focus on hematologic malignancies)
- Curran E, Chen X, Corrales L, Kline DE, Dubensky TW, Duttagupta, Kortylewski M, Kline J. STING activation stimulates potent immunity in a murine myeloid leukemia model. Cell Reports 2016, 15(11):2357-66.
- Curran E and Smith S. Phosphoinositide 3-kinase Inhibitors in Lymphoma. Current Opinion in Oncology 2014, 469-75.
- Curran E and Stock W. How I Treat: Acute Lymphoblastic Leukemia in Older Adolescents and Young Adults (AYAs). Blood 2015, 125(24):3702-10.
- Curran E, Corrales L and Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol 2015, 5:83.
- Curran E and Odenike O. Targeted therapeutic approaches for myelofibrosis. Treatment Strategies – Hematology 2014, 4(1): 23-30.